Bioniche, Synerx Launch Melphalan Hydrochloride

Bioniche and Synerx have announced the FDA approval and launch of Melphalan Hydrochloride for Injection, the generic equivalent of Alkeran from GlaxoSmithKline.

Bioniche and Synerx entered into an agreement whereby Synerx developed and secured the FDA’s approval of Melphalan, and Bioniche holds the exclusive rights to market and distribute Melphalan in the US.

George Zorich, President of US Operations, Bioniche Pharma, said: The launch of Melphalan represents Bioniche’s introduction to the generic injectable oncology market and underscores our commitment to rapid and aggressive product line growth.

We are pleased to have partnered with Synerx and value their expertise in developing this specialty generic product to meet the needs of cancer patients, he added.